Skip to main content

Table 2 Multivariate analyses including microtubule-associated protein Tau (MAPT) expression in all cancers, the ERG negative and ERG positive subset

From: Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer

 

P for PSA recurrence-free survival after prostatectomy

Subset

Scenarioa

N

Preoperative PSA-level

pT-stage

cT-stage

Gleason prostatectomy

Gleason biopsy

pN-stage

R-status

MAPT-expression

All cancers

 

1

6467

< 0.0001

< 0.0001

–

< 0.0001

–

< 0.0001

< 0.0001

< 0.0001

 

2

9690

< 0.0001

< 0.0001

–

< 0.0001

–

–

< 0.0001

< 0.0001

 

3

9545

< 0.0001

–

< 0.0001

< 0.0001

–

–

–

< 0.0001

 

4

8146

< 0.0001

–

< 0.0001

–

< 0.0001

–

–

< 0.0001

ERG-negative

 

1

2541

0.0215

< 0.0001

–

< 0.0001

–

0.0005

0.0601

0.0195

 

2

3873

0.0013

< 0.0001

–

< 0.0001

–

–

< 0.0001

0.0180

 

3

3833

< 0.0001

–

< 0.0001

< 0.0001

–

–

–

0.0013

 

4

3779

< 0.0001

–

< 0.0001

–

< 0.0001

–

–

< 0.0001

ERG-positive

 

1

1900

0.0005

< 0.0001

–

< 0.0001

–

0.0145

0.0010

0.0122

 

2

2995

< 0.0001

< 0.0001

–

< 0.0001

–

–

< 0.0001

0.0185

 

3

2944

< 0.0001

–

< 0.0001

< 0.0001

–

–

–

0.0115

 

4

2900

< 0.0001

–

< 0.0001

–

< 0.0001

–

–

0.0003

  1. aScenario 4 combines preoperatively available parameters (preoperative PSA, clinical tumor (cT) stage, and Gleason grade obtained on the original biopsy) with the postoperative MAPT expression. In scenario 3 the biopsy Gleason is replaced by the Gleason grade obtained on radical prostatectomy. In scenario 2 cT stage is superseeded by pathological tumor (pT) stage and surgical margin (R) status. In scenario 1 the lymph node (pN) stage is added